MARKET

XTLB

XTLB

Xtl Biopharmaceu
NASDAQ
2.230
+0.170
+8.25%
Closed 16:00 06/08 EDT
OPEN
2.270
PREV CLOSE
2.060
HIGH
2.330
LOW
2.080
VOLUME
26.09K
TURNOVER
--
52 WEEK HIGH
10.28
52 WEEK LOW
2.020
MARKET CAP
5.28M
P/E (TTM)
-0.1910
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at XTLB last week (0601-0605)?
Weekly Report · 10h ago
Weekly Report: what happened at XTLB last week (0525-0529)?
Weekly Report · 06/01 10:16
Weekly Report: what happened at XTLB last week (0518-0522)?
Weekly Report · 05/25 10:19
XTL receives Nasdaq staff delist notice for failing to file annual report
Seeking Alpha · 05/22 20:35
XTL Biopharmaceuticals Faces Added Nasdaq Delisting Risk Over Late 2025 Annual Report
TipRanks · 05/22 20:27
XTL Receives Nasdaq Noncompliance Letter
Benzinga · 05/22 20:12
XTL Biopharma seeks Nasdaq trading stay after staff delist determination letter
PUBT · 05/22 20:10
XTL ANNOUNCES RECEIPT OF STAFF DELIST DETERMINATION FROM NASDAQ
Reuters · 05/22 20:10
More
About XTLB
X T L Biopharmaceuticals Ltd (Xenograft Technologies Ltd) is an Israel-based biopharmaceutical company engaged in acquisition and development of pharmaceutical drugs for treatment of autoimmune diseases. The Company pipelines include hCDR1 systematic lupus erythematosus and recombinant human erythropoietin (rHuEPO) multiple myeloma. Its hCDR1, which is a potential treatment for systemic lupus erythematosus (SLE) and Sjogren's syndrome (SS). hCDR1 is a peptide that is administered subcutaneously and acts as a disease-specific treatment to modify the SLE-related autoimmune process. The rHuEPO known agent for anemia to prolong a survival of patients for treatment of multiple myeloma blood cancer. Its Erythropoietin (EPO) is a glycoprotein hormone produced mainly by kidneys. EPO stimulates erythropoiesis, production of red blood cells, by binding to its receptor on a surface of erythroid progenitor cells, promoting their proliferation and differentiation and maintaining their viability.

Webull offers X T L Biopharmaceuticals Ltd (ADR) stock information, including NASDAQ: XTLB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XTLB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading XTLB stock methods without spending real money on the virtual paper trading platform.